1. Information in this forum is not monitored or provided by a medical professional. The information reflects member opinions only. Do not act on advice from these forums without first consulting a qualified medical professional. No professional addiction advisors are recognized by the owners, admins, or moderators, even if the member states such status. All content is copyrighted and protected. DO NOT use any information that can identify you in these forums. If you do, a google search can link your addiction post to your name causing harm to your future activities including employment.

How about HOPEFUL molecular research?

Discussion in 'HEP C HIV' started by gk, Jan 27, 2004.

Thread Status:
Not open for further replies.
  1. gk

    gk Well-Known Member

    Can yo uguys beleive this is the sort of stuff I read, while you folks are watching sitcoms? Scary, huh???

    Love you all,
    Kemin Pharma Developing Two New Molecules That Appear Promising in
    the Battle Against Hepatitis C

    HERENTALS, Belgium, Jan. 12, 2004 /PRNewswire/ -- Kemin Pharma has
    identified two different molecules that appear to have very good
    biological effects against the hepatitis C virus (HCV). The first
    of these molecules is already being tested in Phase II clinical
    trials. Kemin Pharma discovered molecule KPE02003002, a synthetic
    derivative of a phytochemical with several chiral centers, in
    October 2002, through a collaborative effort with the National
    Institutes of Health in Bethesda, Maryland, and the Rega Institute
    for Medical Research in Leuven, Belgium. The second molecule,
    KPE00001113, was discovered in 2003 as part of the same
    collaborative, in vitro, antiviral screening program.

    Kemin's KPE02003002 molecule showed very good biological activity
    against HCV in several in vitro screening assays. Because of these
    promising results, Kemin researchers accelerated the development
    process and completed the first seven-day, clinical Phase II trial
    with the compound used in monotherapy in December of 2003. The
    majority of the patients in this trial were infected with HCV
    genotype 1, the most prevalent genotype in Europe and the United
    States, and had not previously responded to treatment with
    pegylated interferon and ribavirin, the currently available
    treatment. Results of the trial, together with excellent patient
    tolerance, encouraged Kemin researchers to initiate a second Phase
    II trial in first quarter, 2004.

    Kemin's second lead molecule, KPE00001133, is bicyclic carbohydrate
    derivative, a completely different class of compound from the lead
    molecule identified first. Because subsequent toxicity and
    pharmokinetic profiles looked very encouraging, Kemin researchers
    decided to accelerate the product development process for this
    second HCV compound, as well.

    Hepatitis C is a very significant unmet medical need with several
    large pharmaceutical companies actively researching new treatments.
    Worldwide, approximately 170 million people are currently infected
    with HCV, and it is estimated that this number will increase to 500
    million by 2010. There are a number of different forms, or
    genotypes, of HCV with genotype one being the most predominant as
    well as the most difficult to cure. The only treatment currently
    available is a combination of ribavirin with interferon or
    pegylated interferon. This treatment requires up to 48 weeks and
    causes severe side effects for the patients. The success rate is
    very limited, especially against genotype one, with a success rate
    of only 54 percent.

    Kemin Pharma was established in January 2001, as wholly owned,
    independent subsidiary of Kemin Industries, Inc. Its mission is to
    develop new, unique, antimicrobial compounds effective against
    bacteria, viruses and fungi and protozoa that present serious,
    unmet medical challenges throughout the world. Through a
    proprietary prescreening program, Kemin Pharma is focusing its
    screening efforts on compounds that are likely to have a higher
    success rate. This has proven very successful for the company. In
    the first two years of its existence, Kemin researchers have
    isolated and are currently conducting preclinical trials on six
    compounds and Phase II clinical trials on two compounds.
Thread Status:
Not open for further replies.

Share This Page